Vivacta Bio and Grit Bio have secured FDA orphan drug designation for GT801 in autoimmune hemolytic anemia. Early findings from two patients showed complete responses following treatment with the investigational in vivo CAR-T therapy, which uses targeted lipid nanoparticles to generate CD19-directed immune cells inside the body.
Estrella has added Intermountain Health LDS Hospital as the fifth site in its Phase 1/2 STARLIGHT-1 study of EB103. Earlier testing found complete responses in five evaluable patients at the higher dose, but the small uncontrolled dataset and the company's financing position remain important development considerations.
ME Therapeutics extends its CD22 nanobody option to February 2027. Examine dual-target CAR development, licensing and clinical challenges.
Find out how CARsgen’s CT0596 and CT1190B data could reshape the allogeneic CAR T race in cancer therapy.
Find out how Incyte’s tafasitamab data could reshape first-line treatment expectations in high-risk DLBCL.
CAR-T is powerful but hard to scale. Therorna’s circRNA platform tests whether in vivo engineering can move the field beyond bespoke therapy.
Can CTA313 redefine lupus treatment with CAR-T? Explore what Imviva Biotech’s early data means for autoimmune therapy innovation.
Tempest Therapeutics, Inc. advances TPST-2003 CAR-T data. Discover how dual-targeting could impact multiple myeloma treatment durability.
Find out how Tempest Therapeutics, Inc.’s CAR-T strategy could shape the next phase of cell therapy competition and multiple myeloma innovation.
Hinge Bio, Inc. doses first subjects in HB2198 Phase 1 trial. Discover what this could mean for lupus treatment and next-generation immune reset therapies.